ArticleBMC cancer2021
Understanding the patient journey to diagnosis of lung cancer.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System?Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Treatment pathways of lung cancer patients in the Czech Republic: insights from administrative claims data.BMJ open respiratory research · 2026Article
- Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.JCO precision oncology · 2025Article
- Monitoring of the oncological process for lung cancer in Spain: an expert consensus report.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- KPNA2 promotes lung adenocarcinoma progression by inducing glycolysis-assisted MYC nuclear translocation.Cytotechnology · 2025Article
- Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients.Cancer management and research · 2025Review
- Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions.Annals of the American Thoracic Society · 2024Article
- Systems mapping: a novel approach to national lung cancer screening implementation in Australia.Translational lung cancer research · 2024Review
- Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes.Journal of personalized medicine · 2024Review
- Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result.Journal of health economics and outcomes research · 2024Article
- Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.American journal of hypertension · 2024Article
- Optimization System Based on Convolutional Neural Network and Internet of Medical Things for Early Diagnosis of Lung Cancer.Bioengineering (Basel, Switzerland) · 2023Article
- A process to deduplicate individuals for regional chronic disease prevalence estimates using a distributed data network of electronic health records.Learning health systems · 2022Article
- Identification andJournal of thoracic disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis research describes the clinical pathway and characteristics of two cohorts of patients. The first cohort consists of patients with a confirmed diagnosis of lung cancer while the second consists of patients with a solitary pulmonary nodule (SPN) and no evidence of lung cancer. Linked data from an electronic medical record and the Louisiana Tumor Registry were used in this investigation. MATERIALS AND
methodsREACHnet is one of 9 clinical research networks (CRNs) in PCORnet®, the National Patient-Centered Clinical Research Network and includes electronic health records for over 8 million patients from multiple partner health systems. Data from Ochsner Health System and Tulane Medical Center were linked to Louisiana Tumor Registry (LTR), a statewide population-based cancer registry, for analysis of patient's clinical pathways between July 2013 and 2017. Patient characteristics and health services utilization rates by cancer stage were reported as frequency distributions. The Kaplan-Meier product limit method was used to estimate the time from index date to diagnosis by stage in lung cancer cohort.
resultsA total of 30,559 potentially eligible patients were identified and 2929 (9.58%) had primary lung cancer. Of these, 1496 (51.1%) were documented in LTR and their clinical pathway to diagnosis was further studied. Time to diagnosis varied significantly by cancer stage. A total of 24,140 patients with an SPN were identified in REACHnet and 15,978 (66.6%) had documented follow up care for 1 year. 1612 (10%) had no evidence of any work up for their SPN. The remaining 14,366 had some evidence of follow up, primarily office visits and additional chest imaging.
conclusionIn both cohorts multiple biopsies were evident in the clinical pathway. Despite clinical workup, 70% of patients in the lung cancer cohort had stage III or IV disease. In the SPN cohort, only 66% were identified as receiving a diagnostic work-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.